Literature DB >> 3027305

Differential effects of the imidazole derivatives etomidate, ketoconazole and miconazole and of metyrapone on the secretion of cortisol and its precursors by human adrenocortical cells.

S W Lamberts, E G Bons, H A Bruining, F H de Jong.   

Abstract

The direct effects of etomidate, ketoconazole, miconazole and metyrapone were investigated on the secretion of cortisol and its precursors by dispersed cells from the adrenal cortex of a normal individual and four patients with Cushing's syndrome. The drugs interfered with adrenocorticotropic hormone-stimulated cortisol secretion in a dose-dependent way. Desoxycortisol concentrations in the medium were increased after the addition of metyrapone and low doses of etomidate but were suppressed with higher doses of etomidate. The production of 17-hydroxy-progesterone was stimulated by miconazole and metyrapone but was strongly suppressed by the high doses of etomidate. Ketoconazole caused a stimulation of progesterone release, whereas the release of 17-hydroxyprogesterone was suppressed. Finally, the concentration of progesterone was strongly enhanced with high doses of miconazole, whereas etomidate suppressed progesterone production. It is concluded that etomidate at a low concentration (IC50, 10(-8) M) inhibits 11 beta-hydroxylase, whereas, at higher concentrations (10(-7)-10(-6) M), the side-chain cleavage enzyme system is also inhibited; metyrapone is a weaker (IC50, 10(-7) M) but pure 11 beta-hydroxylase inhibitor; miconazole inhibits adrenal 21-hydroxylase at 10(-6) M; and ketoconazole inhibits 17-hydroxylase. Etomidate, ketoconazole, miconazole and metyrapone inhibit cortisol biosynthesis in the human adrenal gland in different manners, which appear to involve the four cytochrome P-450-dependent monooxygenase reactions. Interestingly, these drugs affect corticosteroidogenesis by normal, hyperplastic and adenomatous adrenal cells in a similar manner.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3027305

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  27 in total

1.  Carboetomidate: a pyrrole analog of etomidate designed not to suppress adrenocortical function.

Authors:  Joseph F Cotten; Stuart A Forman; Joydev K Laha; Gregory D Cuny; S Shaukat Husain; Keith W Miller; Hieu H Nguyen; Elizabeth W Kelly; Deirdre Stewart; Aiping Liu; Douglas E Raines
Journal:  Anesthesiology       Date:  2010-03       Impact factor: 7.892

2.  ICU physicians should abandon the use of etomidate!

Authors:  Djillali Annane
Journal:  Intensive Care Med       Date:  2005-01-27       Impact factor: 17.440

3.  Diagnosis and treatment of Cushing's syndrome. Cushing's syndrome: current clinical problems, symposium. Padova, October 19-20, 1990.

Authors: 
Journal:  J Endocrinol Invest       Date:  1992-03       Impact factor: 4.256

Review 4.  Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.

Authors:  Irina Veytsman; Lynnette Nieman; Tito Fojo
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

5.  Adrenal function and ruptured abdominal aortic aneurysm: keeping the hormones in check.

Authors:  A Lisbon; M P Fink
Journal:  Intensive Care Med       Date:  1998-02       Impact factor: 17.440

Review 6.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

Review 7.  Medical therapy of Cushing's disease.

Authors:  Lynnette K Nieman
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

8.  Effect of Angiotensin II and ACTH on Adrenal Blood Flow in the Male Rat Adrenal Gland In Vivo.

Authors:  Abdul J Shah; Tamas Kriska; Kathryn M Gauthier; John R Falck; William B Campbell
Journal:  Endocrinology       Date:  2018-01-01       Impact factor: 4.736

9.  Regulation of steroidogenesis in a primary pigmented nodular adrenocortical disease-associated adenoma leading to virilization and subclinical Cushing's syndrome.

Authors:  Johannes Hofland; Wouter W de Herder; Lieke Derks; Leo J Hofland; Peter M van Koetsveld; Ronald R de Krijger; Francien H van Nederveen; Anelia Horvath; Constantine A Stratakis; Frank H de Jong; Richard A Feelders
Journal:  Eur J Endocrinol       Date:  2012-12-10       Impact factor: 6.664

10.  One single dose of etomidate negatively influences adrenocortical performance for at least 24h in children with meningococcal sepsis.

Authors:  Marieke den Brinker; Anita C S Hokken-Koelega; Jan A Hazelzet; Frank H de Jong; Wim C J Hop; Koen F M Joosten
Journal:  Intensive Care Med       Date:  2007-08-21       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.